ESR2 and breast cancer: As shown in Fig. 6 and Additional file 3: Figure S2, an increased number of mammary tumors that were developed in the absence of ERβ expressed vimentin (7/10; 70%), α-SMA (7/9; 77%), the cytoplasmic active form of B-catenin (7/7; 100%) and N-cadherin (8/9; 88%) or displayed a loss of E-cadherin (6/10; 60%) compared with the K14Crep53F/F mice (vimentin (3/10; 30%), α-SMA (3/9; 33%), B-catenin (0/7; 0%) and N-cadherin (4/9; 44%)).